source
- Samsung Biologics targets $1.8B PolyPeptide buyout to expand in obesityWith PolyPeptide manufacturing peptides such as GLP-1 medicines, Samsung Biologics has identified the deal as a way to tap into fast-growing demand for obesity drug production services.BioSpace · 7d ago↗ source
- Indian generic drugmaker gets FDA warning over clinical study consentIndian generic drugmaker Alembic Pharmaceuticals has been hit with an FDA warning letter after failing to get informed consent from patients for a clinical study. In a breakaway from typical FDA wa…Endpoints · 7d ago↗ source
- FDA plans to name permanent center heads alongside FDA chiefThe FDA is planning to announce a slate of senior personnel announcements when a new commissioner is named, including permanent heads of CBER and CDER, according to three sources familiar with the…